论文部分内容阅读
目的：探讨供者淋巴细胞输注（DLI）防治白血病异基因造血干细胞移植术后复发的疗效及安全性。方法对9例急慢性白血病异基因造血干细胞移植术后患者进行预防性及治疗性DLI，其中移植后复发5例，移植后出现微小残留病（MRD）2例，难治性白血病2例。结果移植后复发5例中再次获完全缓解4例，随访0．9～18个月，2例无病生存，3例死于复发或感染。移植后出现MRD 2例及难治性白血病2例经过DLI后，随访6～24个月，无病生存，MRD未检测到。5例患者DLI后出现移植物抗宿主病。结论 DLI是防治移植后复发的有效方法，可使移植后复发患者取得一定时间缓解，并可清除微小残留病。“,”Objective This study aims to investigate the efficacy of donor lymphocyte infusion (DLI)for the prevention and treatment of relapsed leukemia after hematopoietic stem cell transplantation. Methods Donor lymphocyte infusion was performed on nine leukemia patients after allo-hematopoietic stem cell transplantation. Seven of them received DLI for post-transplant relapse (five cases) and minimal residual disease (two cases),while two of them with refractory leukima received prevention DLI. Results Four of the five cases with relapsed leukemia achieved complete remission after DLI. After a follow-up of 0.9~18 months,two cases remained disease free survival. The other four cases with minimal residual disease(MRD) and refractory disease remained disease free survival after DLI with a follow-up of 6~24 months.The MRD disappeared after DLI. Five patients developed graft-versus-host disease after DLI. Conclusion The use of DLI is an effective therapy to induce durable CR in the treatment of post-transplant relapsed/refractory leukemia,and DLI can eliminate MRD.